28Mar
There has been a panel of FDA advisers that saw it fitting to vote and endorse an experimental stool test pertaining to colon cancer. Colon cancer is deadly, so it’s important to find the precancerous grows and risks before it reaches the point where it can’t be treated. The committee of experts held a vote that ended in a unanimous decision, the ruling sitting at a vote of 10-0. This is in the complete favour of Exact Sciences’ Cologuard test, as it out weighs the “risks” it has to offer immensely.
The FDA doesn’t necessarily have to go with the advisers decision, but they usually do so in the end. “We are pleased the committee strongly supported Cologuards’ approval,” stated Kevin T. Conroy, whom is the chairman and chief executive of Exact Sciences. “We look forward to continuing our work with the FDA to complete its review of Cologuard and remain committed to addressing the growing unmet needs in colorectal cancer screening.”
Doctors have been using stool tests to see if their is hidden traces of blood in their patients fecal matter for some time now, which happens to be a sign of possible tumours, as well as precancerous polyps in the colon. Cologuard and many other DNA tests that are in developmental staged are able to detect the small genetic changes that come with the territory of cancer cells located in the colon.
This past Wednesday a panel of experts from the FDA had voted 5-4, with one advisers not partaking at all, regarding the benefits of using the Epi proColon kit from Epigenomics. This test however makes use of blood, not stool like the previous one stated.
The FDA doesn’t necessarily have to go with the advisers decision, but they usually do so in the end. “We are pleased the committee strongly supported Cologuards’ approval,” stated Kevin T. Conroy, whom is the chairman and chief executive of Exact Sciences. “We look forward to continuing our work with the FDA to complete its review of Cologuard and remain committed to addressing the growing unmet needs in colorectal cancer screening.”
Doctors have been using stool tests to see if their is hidden traces of blood in their patients fecal matter for some time now, which happens to be a sign of possible tumours, as well as precancerous polyps in the colon. Cologuard and many other DNA tests that are in developmental staged are able to detect the small genetic changes that come with the territory of cancer cells located in the colon.
This past Wednesday a panel of experts from the FDA had voted 5-4, with one advisers not partaking at all, regarding the benefits of using the Epi proColon kit from Epigenomics. This test however makes use of blood, not stool like the previous one stated.
via Smart Health Shop Forum http://ift.tt/O4sBlD
No comments:
Post a Comment